May 15, 2020 / 09:00PM GMT
Operator
Hello, everyone, and welcome to the Deciphera Pharmaceuticals QINLOCK FDA Approval Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Robinson, Vice President, Investor Relations. Jen?
Jennifer Robinson - Deciphera Pharmaceuticals, Inc. - VP of IR
Thank you, Sydney. Welcome, and thank you for joining us today to discuss the FDA approval of QINLOCK or ripretinib. The slides that will be shown today are available via webcast and will be posted to the Investor Relations section of our website later today.
I'm Jen Robinson, Vice President, Investor Relations at Deciphera. Joining me today for prepared remarks are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; and Dan Flynn, Founder and Chief Scientific Officer. Tucker Kelly, Chief Financial Officer, will also be joining us during the Q&A session.
Before we begin today, I would like to remind you that any statements we make on this call that are not
Deciphera Pharmaceuticals Inc to discuss the FDA approval of QINLOCK - Conference Call Transcript
May 16, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers